Esperion Therapeutics Files 8-K on Director Changes and Compensation
Ticker: ESPR · Form: 8-K · Filed: Apr 1, 2025 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing
Related Tickers: ESPR
TL;DR
Esperion Therapeutics filed an 8-K on April 1st, updating on board and exec comp. Check for details.
AI Summary
Esperion Therapeutics, Inc. filed an 8-K on April 1, 2025, reporting changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, though specific details of the compensation or financial performance are not elaborated in this summary.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting changes in directors and compensation, with no immediate indication of significant financial distress or operational disruption.
Key Players & Entities
- Esperion Therapeutics, Inc. (company) — Registrant
- April 1, 2025 (date) — Date of Report
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers', but the specific names and details of these changes are not provided in the summary information.
What are the details of the compensatory arrangements mentioned?
The filing notes 'Compensatory Arrangements of Certain Officers' as an item, but the specific terms, amounts, or beneficiaries of these arrangements are not detailed in the provided text.
What financial statements are included in this filing?
The filing states that 'Financial Statements and Exhibits' are included, but the nature or content of these financial statements is not specified.
When was Esperion Therapeutics, Inc. incorporated and in which state?
Esperion Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address and phone number for Esperion Therapeutics, Inc.?
The principal executive offices are located at 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108, and the phone number is (734) 887-3903.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 1, 2025 regarding Esperion Therapeutics, Inc. (ESPR).